News

TB R&D Weekly Update: SQ109 and PNU Compounds Additive

Reddy VM, Dubuisson T, Einck L, Wallis RS, Jakubiec W, Ladukto L, Campbell S, Nacy CA. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother. 2012 Jan 17. [Epub ahead of print]

In this week’s article, we look at two drugs in our Global TB Drug Pipeline and how they interact with each other: SQ109 (class: Ethylenediamines, Sequella) and PNU-100480 (called Sutezolid, class: Oxazolidinone, Pfizer). The authors look at both SQ109 and two PNU compounds (PNU-100480 and PNU-101603) and found that for the most part at concentrations at or below the individual MICs (minimum inhibitory concentrations) there was an additive effect when SQ109 was combined with either compound. An additive interaction can be defined as the effect of two drugs is equal to the sum of the effect of the two drugs taken separately.

Studies such as this one, are important in the development of new treatments for TB which is a disease that must be treated with multiple drugs. The understanding of how different drugs in the Global TB Drug Pipeline interact with one another is critical to the identification of potential new regimens to adequately treat the various stages and forms of the disease, to shorten treatment, and to combat drug resistance.

Additional TB R&D News:

Predicting the in vivo mechanism of action for drug leads using NMR metabolomics

Identifying co-targets to fight drug resistance based on a random walk model

Pyrazinamide: A Frontline Drug Used for Tuberculosis. Molecular Mechanism of Action Resolved after 50 Years?

Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting

Computer simulation of tuberculosis bacteria could lead to discovery of new ways to fight disease

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...